180 related articles for article (PubMed ID: 15932808)
21. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
[TBL] [Abstract][Full Text] [Related]
22. rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H
Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
[TBL] [Abstract][Full Text] [Related]
23. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
24. Clinical trial experience using erythropoietin during radiation therapy.
Lavey RS
Strahlenther Onkol; 1998 Dec; 174 Suppl 4():24-30. PubMed ID: 9879344
[TBL] [Abstract][Full Text] [Related]
25. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin.
Villar A; Martinez JC; de Serdio JL
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1382-8. PubMed ID: 18037586
[TBL] [Abstract][Full Text] [Related]
26. [Erythropoietin and radiation therapy].
Hennequin C
Bull Cancer; 2006 May; 93(5):495-9. PubMed ID: 16777628
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
28. Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma.
Kjellén E; Sasaki Y; Kjellström J; Zackrisson B; Wennerberg J
Acta Otolaryngol; 2006 May; 126(5):545-7. PubMed ID: 16698707
[TBL] [Abstract][Full Text] [Related]
29. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
[TBL] [Abstract][Full Text] [Related]
30. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
31. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
32. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
34. Anemia correction in malignancy management: threat or opportunity?
De Los Santos JF; Thomas GM
Gynecol Oncol; 2007 May; 105(2):517-29. PubMed ID: 17367848
[TBL] [Abstract][Full Text] [Related]
35. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
36. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
[TBL] [Abstract][Full Text] [Related]
37. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
[TBL] [Abstract][Full Text] [Related]
38. Individual patients' data meta-analyses in head and neck cancer.
Bourhis J; Le Maître A; Baujat B; Audry H; Pignon JP; ; ;
Curr Opin Oncol; 2007 May; 19(3):188-94. PubMed ID: 17414635
[TBL] [Abstract][Full Text] [Related]
39. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis.
Lango MN; Andrews GA; Ahmad S; Feigenberg S; Tuluc M; Gaughan J; Ridge JA
Head Neck; 2009 Mar; 31(3):328-37. PubMed ID: 18853450
[TBL] [Abstract][Full Text] [Related]
40. Alternatives to blood product transfusion in the critically ill: erythropoietin.
Stubbs JR
Crit Care Med; 2006 May; 34(5 Suppl):S160-9. PubMed ID: 16617261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
